Roche says Avastin approved in U.S. for type of ovarian cancer

Reuters
A general view shows the headquarter of Swiss drugmaker Roche in Basel July 21, 2008. REUTERS/Christian Hartmann

ZURICH (Reuters) - Roche said on Monday that the U.S. health regulator approved its Avastin drug as a treatment for women with ovarian cancer that is resistant to platinum-containing chemotherapy. Avastin, which is already approved in Europe to treat advanced stages of breast cancer, colorectal cancer, non-small cell lung cancer, kidney cancer and ovarian cancer, was Roche's biggest seller last year with sales of 6.25 billion Swiss francs (6.53 billion US dollar). (Reporting By Katharina Bart; Editing by Himani Sarkar)